KEYTRUDA® (pembrolizumab) KEYNOTE-826 clinical data presentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 2.66 MB
The KEYNOTE-826 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer, whose tumours express PD‑L1 with a CPS ≥1.
CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website